Key indicators: single-crystal X-ray study; T = 153 K; mean (C-C) = 0.004 Å; R factor = 0.032; wR factor = 0.083; data-to-parameter ratio = 14.1.
Data collection
Bruker P4 diffractometer Absorption correction: gaussian (XSCANS; Bruker, 1999) T min = 0.546, T max = 0.705 17640 measured reflections 2460 independent reflections 2127 reflections with I > 2(I) R int = 0.043 Refinement R[F 2 > 2(F 2 )] = 0.032 wR(F 2 ) = 0.083 S = 1.09 2460 reflections 174 parameters H-atom parameters constrained Á max = 0.56 e Å À3 Á min = À0.63 e Å À3 Table 1 Hydrogen-bond geometry (Å , ). Data collection: XSCANS (Bruker, 1999) ; cell refinement: XSCANS; data reduction: XSCANS; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008) ; program(s) used to refine structure: SHELXL97 (Sheldrick, 2008) ; molecular graphics: SHELXTL (Sheldrick, 2008) ; software used to prepare material for publication: SHELXTL.
Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: CV2652).
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Comment
Dapagliflozin is an anti-diabetic agent through the inhibition of renal SGLT2, which is developed by Bristol-Myers Squibb Company, and now it is in the phase III clinical trial (Meng et al., 2008) . During the development of our own SGLT2 inhibitors as anti-diabetic agents, Dapagliflozin was synthesized as the positive control in the bioactivity screening, and the title compound, (I), was prepared as an intermediate. The crystallographic analysis of (I) confirms the molecular structures of the title compound and Dapagliflozin.
In (I) ( Fig. 1 ), all bond lengths are normal and in a good agreement with those reported previously (Allen et al., 1987) .
Two benzene rings (C1-C6 and C8-C13) form a dihedral angle of 69.30 (3) °. In the crystal structure, weak intermolecular C-H···O hydrogen bonds (Table 1 ) link molecules into chains along axis b.
Experimental
A round-bottomed flask was charged with 2.36 g (10 mmol) of 5-bromo-2-chlorobenoic acid, 1 drop of DMF, 1.27 g (10 mmol) of oxalyl chloride and 3 ml of dried dichloromethane, and the mixture was stirred at room temperature over night until a clear solution formed. The reaction mixture was evaporated on a rotary evaporator to give crude 5-bromo-2-chlorobenzoic acid, which was dissolved in 15 ml of dried dichloromethane. The solution thus obtained was stirred while being cooled with an ice-salt mixture, and 1.22 g (10 mmol) of phenetole was added followed by addition of 1.60 g (12 mmol) of anhydrous aluminium chloride in a portionwise manner. The resulting mixture was stirred at this temperature for 1 h and poured into 150 ml of ice-water. The mixture thus formed was exacted with three 50-ml portions of dichloromethane, and the combined exacts were washed with saturated brine, dried over sodium sulfate and evaporated on a rotary evaporator to afford the crude title compound. Pure title compound was obtained by column chromatography (2.86 g 84.2%). Crystals suitable for X-ray diffraction were obtained through slow evaporation of a solution of the pure title compound in dichloromethane/ethyl acetate/petroleum ether (2/1/3 by volume).
Refinement
All C-bound H atoms were placed in calculated positions, with C-H = 0.93-0.97 Å, and included in the final cycles of refinement using a riding model, with U iso (H) = 1.2U eq (C) for the aryl and methylene H atoms and 1.5U eq (C) for the methyl H atoms. Fig. 1 . View of the title compound, with displacement ellipsoids drawn at the 40% probability level.
Figures
(5-Bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone (19) C9-C10-C11 119.0 (2) C6-C1-Cl1 119.9 (2) C9-C10-H10 120.5 C1-C2-C3 120.1 (2) C11-C10-H10 120.5
Hydrogen-bond geometry (Å, °) supplementary materials sup-6 Fig. 1 
